Shaun Grady, formerly vice president for corporate business development at AstraZeneca, has been appointed vice president for business development and licensing responsible for the company’s relationships with external partners. He replaces John Goddard who has retired. Mr Grady is a 23-year veteran of AstraZeneca having spent much of his time in corporate legal affairs. In his new role, he will report to the group chief financial officer, Simon Lowth. Separately, AstraZeneca announced the appointment of Menelas Pangalos as executive vice president of innovative medicines, effective 1 May 2010. A former chief scientific officer for neuroscience research at Pfizer Inc, Mr Pangalos will lead AstraZeneca’s discovery research and early drug development activities.
Copyright 2010 Evernow Publishing Ltd